Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health‐related...

Descripción completa

Detalles Bibliográficos
Autores principales: Larocca, Alessandra, Leleu, Xavier, Touzeau, Cyrille, Bladé, Joan, Paner, Agne, Mateos, María‐Victoria, Cavo, Michele, Maisel, Christopher, Alegre, Adrían, Oriol, Albert, Raptis, Anastasios, Rodriguez‐Otero, Paula, Mazumder, Amitabha, Laubach, Jacob, Nadeem, Omar, Sandberg, Anna, Orre, Marie, Torrång, Anna, Bakker, Nicolaas A., Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy–Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135124/
https://www.ncbi.nlm.nih.gov/pubmed/34671975
http://dx.doi.org/10.1111/bjh.17887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135124/
https://www.ncbi.nlm.nih.gov/pubmed/34671975
http://dx.doi.org/10.1111/bjh.17887

Ejemplares similares